
    
      The purpose of this clinical trial is to determine if peptide receptor radiotherapy (PRRT)
      using 177Lu-DOTA-OCTREOTATE given intravenously in children and adolescents is an effective
      treatment and to describe its toxicities.

      This study will consists of children and adolescents ages 1-20 years with relapsed or
      refractory neuroendocrine tumors and pheochromocytoma or paraganglioma.
    
  